Business
Medicure to Announce Q1 2016 Financial Results on May 11, 2016
Medicure to Announce Q1 2016 Financial Results on May 11, 2016 Medicure to Announc...
About this update from Medicure Inc.
[{"type":"text","content":"\n\n\n\nMedicure to Announce Q1 2016 Financial Results on May 11, 2016\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMedicure to Announce Q1 2016 Financial Results on May 11, 2016\nCanada NewsWire\nWINNIPEG, May 4, 2016\n\n\n\nWINNIPEG, May 4, 2016 /CNW/ - Medicure Inc. (\"Medicure\") (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, will release financial results for the first quarter ended March 31, 2016 after market close on Wednesday, May 11, 2016. Medicure will hold a conference call and webcast regarding the results on Thursday, May 12 2016, at 7:30 AM Central Time (8:30 AM Eastern Time).\n\nConference Call Info:\n\nTopic:  Medicure's Q1 2016 Results\n\nCall date:  Thursday, May 12, 2016\n\nTime:  7:30 AM Central Time (8:30 AM Eastern Time)\n\nCanada toll-free:  1 (888) 465-5079   (Canada Toll: 1 (416) 216-4169)\n\nUnited States toll-free:  1 (888) 545-0687\n\nPasscode:  8920023 #            \n\nWebcast:    This conference call will be webcast live over the internet and can be accessed from the Medicure investor relations page at the following link: http://www.medicure.com/investors.html  \n\nYou may request international country-specific access information by e-mailing the company in advance. Management will accept and answer questions related to the financial results and its operations during the question-and-answer period at the end of the conference call. A recording of the call will be available following the event at the company's website.\n\nAbout Medicure Inc.\n\nMedicure is a specialty pharmaceutical company focused on the development and commercialization of therapeutics for the U.S. hospital market.  The primary focus of the Company and its subsidiaries is the marketing and distribution of AGGRASTAT (tirofiban HCl) for non-ST elevation acute coronary syndrome in the United States, where it is sold through the Company's U.S. subsidiary, Medicure Pharma, Inc.  For more information on Medicure please visit ww...